Key result
Combined immunosuppression for giant cell myocarditis yields only temporary improvement before fatal complications.
Why the study?
Idiopathic giant cell myocarditis is an uncommon, frequently fatal myocarditis that primarily affects young individuals, prompting the presentation of an unusual case in an older adult alongside a review of its natural history and treatment.
Case Report (n=1)
No
Idiopathic giant cell myocarditis is a rare and rapidly progressive autoimmune condition that requires early diagnosis via endomyocardial biopsy and aggressive combined immunosuppression or heart transplantation to improve long-term outcomes.
Answers are grounded in this paper and cite their sources.
Emphasizes risks of profound immunosuppression in giant cell myocarditis; leaves open need for better-tolerated therapies in this rare condition.
BACKGROUND Idiopathic giant cell myocarditis (IGCM) is an uncommon and frequently fatal type of myocarditis. It primarily affects young individuals and has the potential to result in heart failure and life-threatening arrhythmias. IGCM seems to be dependent on activation of CD4-positive T lymphocytes and can show improvement with treatment aimed at reducing T-cell function. We present a case of a 65-year-old patient who presented with features of acute heart failure refractory to guideline-directed medical therapy (GDMT), due to IGCM. A review of the natural history and treatment of IGCM is also presented. CASE REPORT A 65-year-old woman with multiple comorbidities was admitted to our hospital for ventricular tachycardia in the setting of progressive non-ischemic heart failure, unresponsive to GDMT. This led to further investigation, including an endomyocardial biopsy, which revealed inflammatory infiltration, with multinucleated giant cells and lymphocytes in the absence of granuloma formation, prompting a diagnosis of IGCM. An implantable cardioverter-defibrillator (ICD) was placed for secondary prevention of sudden cardiac death and the patient was initiated on combined immunosuppressive therapy. Owing to numerous comorbidities, she was determined to be unsuitable for a heart transplant. Unfortunately, she eventually died from complications secondary to the disease. CONCLUSIONS IGCM remains a challenging clinical diagnosis with a poor long-term outcome without heart transplantation. This case highlights the importance of considering atypical causes of heart failure in patients who do not respond to conventional therapies. Early recognition and appropriate management, involving medical and interventional approaches, are crucial in improving outcomes for patients with IGCM.
No takes yet. Share an insight, caveat, or question.
González-Moret et al. (2024) conducted a case report in Idiopathic Giant Cell Myocarditis (n=1). Combined immunosuppressive therapy and implantable cardioverter-defibrillator was evaluated. A 65-year-old woman with idiopathic giant cell myocarditis treated with combined immunosuppression initially improved but eventually died from complications of the disease and profound immunosuppression.
Synapse has enriched 10 related papers. Consider them for comparative context: